Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Revenue of Tempest Therapeutics, Inc. (TPST)
Revenue in 2023 (TTM): $
According to Tempest Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Tempest Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-381,000 | $-28,776,000 | $-29,491,000 | $-29,491,000 |
| 2022 | $ | $-1,814,000 | $-32,277,000 | $-35,709,000 | $-36,778,000 |
| 2021 | $ | $-1,270,000 | $-25,716,000 | $-28,302,000 | $-29,550,000 |
| 2020 | $ | $-815,000 | $-18,393,000 | $-19,208,000 | $-19,118,000 |
| 2019 | $ | $-1,052,000 | $-43,516,000 | $-44,568,000 | $-44,568,000 |
| 2018 | $ | $-32,000 | $-27,011,000 | $-27,177,000 | $-27,192,000 |
| 2017 | $295 K | $267 K | $-84,270,000 | $-84,586,000 | $-84,578,000 |
| 2016 | $653 K | $-4,748,000 | $-79,821,000 | $-82,059,000 | $-82,260,000 |
| 2015 | $277 K | $-1,972,000 | $-71,858,000 | $-73,144,000 | $-73,219,000 |
| 2014 | $9.74 M | $9.74 M | $-49,070,000 | $-49,520,000 | $-49,520,000 |
| 2013 | $ | $ | $-28,813,000 | $-29,044,000 | $-29,044,000 |
| 2012 | $ | $ | $-13,529,000 | $-13,510,000 | $-13,510,000 |